Josh Enomoto

Josh Enomoto

InvestorPlace Contributor

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Acasti Pharma Stock Is Bleeding Both Value and Credibility

By Josh Enomoto, InvestorPlace Contributor

Acasti Pharma stock jumped higher last year on the potential of Acasti’s krill-oil extract CaPre. But a closer examination of its Phase 3 results suggests not all is well with the company.

Roku Stock Might Receive a Fourth-Quarter Earnings Boost

By Josh Enomoto, InvestorPlace Contributor

Roku stock faces a key earnings test in fourth quarter. But if recent trends are anything to go by, the streaming company should do well.

Tailwinds Don’t Necessarily Make Intel Stock a Buy Here

By Josh Enomoto, InvestorPlace Contributor

With Intel putting up some surprising results for Q4, Intel stock appears a viable candidate for a long-term recovery. However, in the immediate framework, the coronavirus presents substantial concerns.

3 Pros and 3 Cons For INO Stock Amid Chinese Coronavirus Outbreak

By Josh Enomoto, InvestorPlace Contributor

Several factors both cloud and bolster the narrative for INO stock. Ultimately though, the underlying company’s technology is worth a speculative gamble.

Steer Clear of YETI Stock Ahead of Q4

By Josh Enomoto, InvestorPlace Contributor

YETI stock killed it in 2019 thanks to the underlying company’s reliable and robust outdoors products. However, industry credibility concerns and competitive risks make YETI a tough buy ahead of Q4.

Load More